Relay Therapeutics (NASDAQ:RLAY) – Why Relay Therapeutics Shares Are Getting HammeredBenzinga • 09/13/22
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay's Investigational FGFR2 Inhibitor, RLY-4008Business Wire • 09/12/22
Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven DiseaseGlobeNewsWire • 09/11/22
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate HighlightsGlobeNewsWire • 07/28/22
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor EventGlobeNewsWire • 06/27/22
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare ConferenceGlobeNewsWire • 05/03/22
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate HighlightsGlobeNewsWire • 02/24/22
Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate HighlightsGlobeNewsWire • 02/17/22
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/22
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in CombinationGlobeNewsWire • 12/10/21
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/10/21
Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/04/21
Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board MemberBusiness Wire • 10/14/21
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 InhibitorGlobeNewsWire • 10/08/21
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3KαGlobeNewsWire • 10/07/21
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets ConferenceGlobeNewsWire • 09/13/21
Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/05/21
Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation SummitGlobeNewsWire • 05/14/21
Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.GlobeNewsWire • 05/10/21